Aardvark Therapeutics (AARD) announced that the first patient has been dosed in Australia in its Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome. Additionally, regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom has also been received. Based on enrollment in the U.S. and continued progress in advancing the clinical trial internationally, the clinical trial continues to track towards a topline data readout in Q3 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Closing Bell Movers: Marvell up 11%, reversing initial earnings selloff
- Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation
- Aardvark Therapeutics initiated with a Strong Buy at Raymond James
- Aardvark Therapeutics Reports Q3 2025 Financial Results
- Aardvark Therapeutics reports Q3 EPS (75c), consensus (80c)